A Phase I Study to Investigate the Relative Bioavailability of Modified-release Formulations of AZD1446 Compared to an Immediate-release Capsule Under Fed and Fasting Conditions Following Single and Repeated Dose Administration to Young and Elderly Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2015
At a glance
- Drugs AZD 1446 (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 26 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 26 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Mar 2010 New trial record